In the Bystolic case, Faruqi & Faruqi represents a proposed class of direct purchasers of Forest Laboratories’ (now AbbVie) blood pressure drug, Bystolic. The complaint alleges that Forest entered into reverse payment agreements with several would-be generic competitors to delay market entry of their generic Bystolic products.
Send Information
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.
Details
Filed on 07/23/2020
Office
1617 JFK Boulevard, Suite 1550
19103 Philadelphia, Pennsylvania
Phone (215) 277-5770
Fax (215) 277-5771
Counsel
Joseph T. Lukens jlukens@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771
Peter Kohn pkohn@faruqilaw.com Phone (215) 277-5770 Fax (215) 277-5771